Asuragen

Asuragen test kits to detect major and minor BCR-ABL fusions can now run on the Roche Diagnostics Cobas z 480 Analyzer.

Under the collaboration, Asuragen will develop diagnostic kits for analyzing repeat sequences using Thermo Fisher's 3500 Dx Series Genetic Analyzer CS2 instrument.

The molecular test is now the first FDA-cleared assay to monitor treatment response and disease clearance in chronic myeloid leukemia patients.

When molecular testing did affect the surgical plan, it often led to overtreatment, according to the Johns Hopkins University School of Medicine team.

Asuragen will leverage its Quantidex NGS product platform and Illumina's FDA-cleared MiSeqDx instrument to develop companion diagnostics.

The assay improves upon other tests by attaining a sensitivity of MR4.7 while it allows direct reporting on the IS, Asuragen said.

Caprion, Asuragen, and the AIT Austrian Institute of Technology join the consortium launched in 2013 to develop blood-based tests for the early detection of cancers.